- Home
- ANIX vs AVTX Comparison
ANIX vs AVTX Comparison
Compare ANIX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- AVTX
- Stock Information
- Founded
- ANIX 1982
- AVTX 2011
- Country
- ANIX United States
- AVTX United States
- Employees
- ANIX N/A
- AVTX N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- AVTX Health Care
- Exchange
- ANIX Nasdaq
- AVTX Nasdaq
- Market Cap
- ANIX 82.7M
- AVTX 77.7M
- IPO Year
- ANIX 1987
- AVTX 2015
- Fundamental
- Price
- ANIX $2.41
- AVTX $6.75
- Analyst Decision
- ANIX Strong Buy
- AVTX Strong Buy
- Analyst Count
- ANIX 2
- AVTX 4
- Target Price
- ANIX $8.50
- AVTX $33.00
- AVG Volume (30 Days)
- ANIX 121.1K
- AVTX 137.5K
- Earning Date
- ANIX 01-10-2025
- AVTX 11-07-2024
- Dividend Yield
- ANIX N/A
- AVTX N/A
- EPS Growth
- ANIX N/A
- AVTX N/A
- EPS
- ANIX N/A
- AVTX N/A
- Revenue
- ANIX N/A
- AVTX $820,000.00
- Revenue This Year
- ANIX N/A
- AVTX N/A
- Revenue Next Year
- ANIX N/A
- AVTX N/A
- P/E Ratio
- ANIX N/A
- AVTX N/A
- Revenue Growth
- ANIX N/A
- AVTX N/A
- 52 Week Low
- ANIX $2.07
- AVTX $4.01
- 52 Week High
- ANIX $5.09
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- ANIX 44.08
- AVTX 32.78
- Support Level
- ANIX $2.07
- AVTX $5.99
- Resistance Level
- ANIX $2.69
- AVTX $7.17
- Average True Range (ATR)
- ANIX 0.19
- AVTX 0.91
- MACD
- ANIX 0.03
- AVTX -0.05
- Stochastic Oscillator
- ANIX 54.84
- AVTX 23.17
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).